Related Experiment Videos
Timing of magnesium therapy affects experimental infarct size
W R Herzog1, M L Schlossberg, K S MacMurdy
1University of Maryland Medical Center, Department of Medicine, Baltimore 21201, USA.
Background:
Controversy exists regarding the use of magnesium in the treatment of acute myocardial infarction (AMI) because of apparent conflicting results from clinical trials. One hypothesis to explain the various clinical observations proposes that the timing of magnesium administration significantly influences its therapeutic effect; ie, supraphysiological levels of Mg2+ must be present at the time of reperfusion for magnesium to produce clinical benefit.
Methods And Results:
These experiments evaluated the effect of varying the timing of magnesium administration during AMI. Female Yorkshire swine (34 to 42 kg) underwent thoracotomy and 50 minutes of left anterior descending coronary artery (LAD) occlusion, followed by 3 hours of reperfusion. In the first group, MgSO4 (250 mg of magnesium diluted in 60 cm3 saline) was infused into the LAD over 12 minutes, beginning immediately with the onset of reperfusion (n = 6, Mg-early group). In the second group, MgSO4 was given after 1 hour of reperfusion (n = 6, Mg-late group). Six pigs received saline instead of magnesium and served as the control group. Lethal arrhythmias were significantly reduced in the Mg-early group. Infarct size was determined by vital staining. Infarct size was 0.16 +/- 0.05 g/kg body wt (Mg-early), 0.35 +/- 0.08 g/kg (Mg-late), and 0.42 +/- 0.04 g/kg for the control group. Compared with the control group, significant (P = .029) reduction in infarct size occurred in the Mg-early group but not in the Mg-late group.
Conclusions:
We conclude that intracoronary MgSO4 delivered during reperfusion can significantly diminish infarct size in swine, but the timing of administration is critical.
Insights
Administering magnesium sulfate early during reperfusion significantly reduces infarct size in acute myocardial infarction (AMI) models. Timely magnesium administration is critical for its therapeutic benefit in AMI treatment.
Area of Science:
- Cardiology
- Pharmacology
- Experimental Medicine
Background:
- Conflicting clinical trial results exist regarding magnesium's efficacy in treating acute myocardial infarction (AMI).
- A key hypothesis suggests that the timing of magnesium administration is crucial for its therapeutic effect during AMI.
- Supraphysiological magnesium levels at reperfusion may be necessary for clinical benefit.
Purpose of the Study:
- To evaluate the impact of magnesium administration timing on therapeutic outcomes in an AMI model.
- To investigate whether early versus late magnesium delivery influences infarct size and arrhythmias.
Main Methods:
- Female Yorkshire swine underwent coronary artery occlusion followed by reperfusion.
- Magnesium sulfate (MgSO4) was administered either immediately upon reperfusion (Mg-early) or after one hour (Mg-late).
- Control groups received saline; lethal arrhythmias and infarct size were assessed.
Main Results:
- Early administration of MgSO4 significantly reduced lethal arrhythmias.
- Intracoronary MgSO4 delivered during reperfusion significantly diminished infarct size in the Mg-early group compared to controls (P = .029).
- The Mg-late group did not show a significant reduction in infarct size compared to the control group.
Conclusions:
- Intracoronary magnesium sulfate administered during reperfusion can significantly reduce infarct size in a swine model of AMI.
- The timing of magnesium administration is a critical factor determining its efficacy in mitigating myocardial damage.